Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLX51107 |
Synonyms | |
Therapy Description |
PLX51107 is a small molecule BET inhibitor, which binds to BET bromodomains in BRD2, BRD3, BRD4, and BRDT, potentially resulting in decreased tumor cell proliferation (PMID: 29386193, PMID: 31063649, PMID: 32717030). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLX51107 | PLX-51107|PLX 51107 | BET Inhibitor (Pan) 32 | PLX51107 is a small molecule BET inhibitor, which binds to BET bromodomains in BRD2, BRD3, BRD4, and BRDT, potentially resulting in decreased tumor cell proliferation (PMID: 29386193, PMID: 31063649, PMID: 32717030). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |